Vascular effects of apelin in vivo in man

Citation for published version:

Digital Object Identifier (DOI):
10.1016/j.jacc.2008.06.013

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of the American College of Cardiology

Publisher Rights Statement:
Available under Open Access

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Vascular Effects of Apelin In Vivo in Man

Alan G. Japp, MRCP,* Nicholas L. Cruden, PhD,* David A. B. Amer,* Vivienne K. Y. Li, BSc,* Ewan B. Goudie, BSc,* Neil R. Johnston, MSc,* Sushma Sharma, PhD,† Ilene Neilson, BSc,C,† David J. Webb, MD, FRCP,* Ian L. Megson, PhD,† Andrew D. Flapan, MD, MRCP,‡ David E. Newby, PhD, FRCP*

Edinburgh and Inverness, United Kingdom

Objectives
This study was designed to establish the direct vascular effects of apelin in vivo in man.

Background
Apelin is the endogenous ligand for the previously orphaned G-protein–coupled receptor, APJ. This novel pathway is widely expressed in the cardiovascular system and is emerging as an important mediator of cardiovascular homeostasis. In pre-clinical models, apelin causes venous and arterial vasodilation.

Methods
Vascular effects of apelin were assessed in 24 healthy volunteers. Dorsal hand vein diameter was measured by the Aellig technique during local intravenous infusions (0.1 to 3 nmol/min) of apelin-36, (Pyr1)apelin-13, and sodium nitroprusside (0.6 nmol/min). Forearm blood flow was measured by venous occlusion plethysmography during intrabrachial infusions of apelin-36 and (Pyr1)apelin-13 (0.1 to 30 nmol/min) and subsequently in the presence or absence of a “nitric oxide clamp” (nitric oxide synthase inhibitor, L-N^G-monomethylarginine [8 μmol/min], coinfused with nitric oxide donor, sodium nitroprusside [90 to 900 ng/min]), or a single oral dose of aspirin (600 mg) or matched placebo.

Results
Although sodium nitroprusside caused venodilation (p < 0.0001), apelin-36 and (Pyr1)apelin-13 had no effect on dorsal hand vein diameter (p = 0.2). Both apelin isoforms caused reproducible vasodilation in forearm resistance vessels (p < 0.0001). (Pyr1)apelin-13–mediated vasodilation was attenuated by the nitric oxide clamp (p = 0.004) but unaffected by aspirin (p = 0.7).

Conclusions
Although having no apparent effect on venous tone, apelin causes nitric oxide–dependent arterial vasodilation in vivo in man. The apelin-APJ system merits further clinical investigation to determine its role in cardiovascular homeostasis. (J Am Coll Cardiol 2008;52:908–13) © 2008 by the American College of Cardiology Foundation

Apelin is the endogenous ligand for the orphan G-protein–coupled receptor, APJ (1,2). The full-length mature peptide, apelin-36, comprises 36 amino acids but the most potent isoform is the pyroglutamated form of apelin-13, (Pyr1)apelin-13 (2–4). The APJ receptors are present on endothelial cells, vascular smooth muscle cells, and cardiomyocytes (5).

In rodent models, exogenous apelin administration causes a rapid nitric oxide (NO)–dependent fall in blood pressure and mean capillary filling pressure, indicating powerful vasodilator and venodilator effects (3). In ex vivo myography studies, apelin causes NO-dependent vasorelaxation in human mesenteric arteries (6) and venoconstriction in endothelium-denuded human saphenous veins (7). As a first step toward characterizing the in vivo cardiovascular profile of apelin in man, we sought to determine its direct vasomotor effects in the peripheral venous and arterial circulation.

Methods

Subjects. Twenty-four healthy male volunteers (age 19 to 24 years) participated following written informed consent, with the approval of the local research ethics committee, and in accordance with the Declaration of Helsinki. Participants were not taking regular medication and abstained from alcohol for 24 h and from food and caffeine-containing drinks for at least 4 h before studies.

Vascular studies. Studies were conducted in a quiet temperature-controlled room (22°C to 25°C). Heart rate and blood pressure were monitored at regular intervals with a semi-automated, oscillometric sphygmomanometer (HEM 705CP, Omron, Tokyo, Japan).
VENOUS STUDIES. Intravenous infusions (0.25 ml/min) were administered through a 23-gauge needle in a non-branching dorsal hand vein (DHV). Venous tone was measured by the Aellig technique during norepinephrine (Hospira, Illinois; 1 to 32 ng/min) preconstriction (50% to 70% reduction in diameter) as described previously (8). Six subjects (Fig. 1, protocol 1) received incremental infusions of (Pyr1)apelin-13 or apelin-36 (Clinalfa AG, Läufelfingen, Switzerland; 0.1 to 3 nmol/min) followed, after saline washout, by a single dose of sodium nitroprusside (SNP) (Mayne Pharma Plc, Warwickshire, United Kingdom) at 0.6 nmol/min. A further 3 subjects received (Pyr1)apelin-13 and apelin-36 in the absence of norepinephrine preconstriction.

ARTERIAL STUDIES. Intra-arterial infusions (1 ml/min) were administered through a 27-standard-wire-gauge steel brachial artery needle. Forearm blood flow (FBF) was measured in both forearms by venous occlusion plethysmography as described previously (9,10). In protocol 2A, blood samples (10 ml) were drawn from each arm into ethylenediaminetetraacetic acid and centrifuged to obtain plasma that was stored at −80°C. Plasma apelin concentrations were measured using a commercially available enzyme-linked immunosorbant assay (Phoenix Pharmaceuticals Inc., Burlingame, California.). In protocol 3, a “NO clamp” (L-NMMA-monomethylarginine [8 μmol/min] coinfused with SNP [90 to 900 ng/min]) was used to allow simulation of normal basal NO activity during complete inhibition of endogenous NO synthesis, as described previously (11). Dispersible aspirin (600 mg; Aspar Pharmaceuticals Ltd., London, United Kingdom) was administered orally 30 min before study commencement to inhibit production of prostaglandins (12).

Eight subjects attended on 4 occasions at least 1 week apart to receive incremental infusions of apelin-36 or (Pyr1)apelin-13 (0.1 to 30 nmol/min) in the presence and absence of saline washouts (protocol 2). A further 8 subjects attended on 4 occasions to receive, in a randomized order: 1) the NO clamp and oral aspirin; 2) the NO clamp and oral placebo; 3) saline placebo and oral aspirin; and 4) saline placebo and oral placebo, followed on all occasions by sequential infusions of (Pyr1)apelin-13 (0.3 to 3 nmol/min) and acetylcholine (Novartis AG, Basel, Switzerland; 5 to 20 μg/min) in a double-blind manner (protocol 3).
Data and statistical analyses. The DHV (13) and FBF (9) data were analyzed as described previously. The effects of the NO clamp and aspirin on FBF responses to (Pyr1)apelin-13 and acetylcholine were assessed by calculating area under the curve (AUC) using the trapezoid method. Apelin concentrations were logarithmically transformed prior to analysis. Variables are reported as mean ± standard error of mean and analyzed using repeated-measures analysis of variance (ANOVA) with post-hoc Bonferroni corrections, regression analysis, and 2-tailed Student t test as appropriate (Graph-Pad Prism, GraphPad Software, Inc., San Diego, California). Statistical significance was taken at the 5% level.
Results

In all studies, apelin infusions were well tolerated with no serious adverse events. There were no changes in heart rate or blood pressure.

Neither (Pyr1)apelin-13 nor apelin-36 caused venoconstriction in relaxed DHVs (data not shown). Following preconstriction, DHV diameter was unaffected by (Pyr1)apelin-13 (p = 0.18, 1-way ANOVA) or apelin-36 (p = 0.24, 1-way ANOVA) but increased by SNP (p = 0.0001) (Fig. 2).

(Pyr1)apelin-13 and apelin-36 increased FBF in the infused arm (p < 0.001) (Figs. 3 and 4). Vasodilation to apelin-36 was dose-dependent (r² = 0.41, p < 0.0001) but plateaued rapidly with (Pyr1)apelin-13 (r² = 0.003, p = 0.73). After continuous dose escalation of each apelin isoform, FBF declined gradually over 42 min (for both: p < 0.0001, ANOVA). With apelin-36, FBF remained elevated during saline washout (p < 0.0001) and failed to rise further during subsequent reinfusion (Fig. 3). With (Pyr1)apelin-13, FBF remained elevated at 6 min during saline washout (p < 0.05) but not thereafter, and further vasodilation was demonstrable during subsequent reinfusion (p < 0.0001) (Fig. 3).

At the highest dose of 30 nmol/min, infused FBF was greater with apelin-36 compared with (Pyr1)apelin-13 (p < 0.05) (Fig. 3B). The inclusion of saline washouts between doses did not affect vasodilation to either (Pyr1)apelin-13 (p = 0.68) (Fig. 4B) or apelin-36 (p = 0.93) (Fig. 4C). With both apelin isoforms, FBF increased in the noninfused arm (p < 0.0001, ANOVA) at 30 nmol/min (p < 0.05, post-hoc Bonferroni tests; data not shown).

Plasma apelin concentrations in the infused arm rose with increasing doses of apelin-36 (p < 0.0001) (Fig. 5) and increased in the noninfused arm from 10 nmol/min (p < 0.01). L-N²-monomethylarginine reduced infused FBF (3.48 ± 0.41 ml/100 ml/min to 2.10 ± 0.17 ml/100 ml/min; p < 0.01).

Figure 4 Infused FBF

Infused FBF (A) in protocol 2B during infusion of (Pyr1)apelin-13 (top, solid squares; 1-way ANOVA) and apelin-36 (bottom, open squares; 1-way ANOVA) and during incremental infusion of (Pyr1)apelin-13 (B) and apelin-36 (C) in the presence (solid squares) and absence (open squares) of saline washouts (for both: p > 0.05, 2-way ANOVA with repeated measures). **p < 0.01, ***p < 0.001, post-hoc Bonferroni tests. Abbreviations as in Figure 3.

Figure 5 Plasma Apelin Concentration

Plasma apelin concentration in venous blood samples from infused (solid bars) and noninfused arm (open bars) during intrabrachial apelin-36 infusion. **p < 0.01, ***p < 0.001, 1-way ANOVA with post-hoc Bonferroni tests. Abbreviation as in Figure 3.
but this was restored with SNP coinfusion (3.20 ± 0.33 ml/100 ml/min; p > 0.05 vs. baseline). Both
(Pyr1)apelin-13 (p < 0.001) and acetylcholine (p < 0.001)
increased infused FBF (Fig. 6). Coinfusion of the NO
clamp inhibited the response to (Pyr1)apelin-13 (AUC: 4.7
± 0.9 AU vs. 1.7 ± 0.7 AU; p = 0.004) and acetylcholine
(AUC: 12.8 ± 2.3 AU vs. 6.4 ± 1.5 AU; p = 0.02) but
aspirin had no effect (p > 0.05 for both) (Fig. 6).

Discussion

This is the first study to examine the in vivo vascular actions of
apelin in man. Using robust well-validated techniques, we have
assessed the direct effects of 2 endogenous apelin isoforms on
vascular tone. Although not affecting peripheral venous tone,
apelin peptides cause vasodilation in peripheral resistance
vessels through a NO-dependent mechanism.

Effects of apelin on peripheral arteriolar tone. In keeping
with pre-clinical models and studies of human mesenteric
vessels in vitro, we have demonstrated that apelin causes
reproducible vasodilation in human forearm resistance vessels
in vivo. We studied 2 different apelin isoforms, apelin-36 and
(Pyr1)apelin-13, and both caused a rapid onset of vasodilation.
Apelin-36 exhibited a slower offset, with vasodilation persisting
for at least 42 min after cessation of infusion. This
prolonged offset of action is unusual but has been described
with other agonists, such as the V2 agonist, desmopressin (14).

It is consistent with in vitro data showing that apelin-36
exhibits a much slower dissociation from the APJ receptor than
(Pyr1)apelin-13 and causes prolonged biological activity in
microphysiometric assays (4). In addition, apelin appears to be
rapidly cleared from the circulation with a short plasma
half-life of no longer than 8 min. Although shorter apelin
peptides have more potent depressor activity in rats (15), we
saw no difference in potency between the 2 isoforms and a
greater response to apelin-36 at the highest dose. This was due,
at least in part, to a plateauing of the response to
(Pyr1)apelin-13 at higher doses that may have resulted from
APJ receptor internalization (16) combined with a shorter
duration of receptor activation.

Vasodilation to (Pyr1)apelin-13 was attenuated by two-
thirds during the NO clamp, indicating that vasodilation to
apelin is mediated predominantly by endothelial NO genera-
tion. As expected, the NO clamp also inhibited acetylcholine-
mediated vasodilation, which is known to be partly mediated
by NO (17). In contrast, systemic inhibition of prostanooid
generation with oral aspirin did not alter vasodilation to either
(Pyr1)apelin-13 or acetylcholine, alone or in combination with
the NO clamp. The dose of aspirin used in this study inhibits
bradykinin-induced endothelial production of prostacyclin by
at least 85% (12), suggesting that prostanooids do not provide a
major contribution to apelin-mediated vasodilation. Our in
vivo findings are in close agreement with Salcedo et al. (6) who
recently demonstrated that NO synthase, but not cyclooxygenase, inhibition attenuated relaxation to apelin in human mesenteric arteries in vitro.

**Effects of apelin on peripheral venous tone.** We demonstrated constrictor and dilator responses to norepinephrine and SNP, respectively, and employed doses of apelin 10-fold higher than those required to cause vasodilation in the forearm arterial circulation. It is unlikely therefore that the lack of venous response to apelin reflected either inadequate dosing or sensitivity of the technique. However, we examined the effects of apelin in a single peripheral venous bed and cannot exclude the possibility of a direct effect on central capacitance veins. Further clinical studies are required to determine the in vivo effects of apelin in specific venous beds and on overall systemic venous tone.

**Study limitations.** We measured changes in FBF and plasma apelin concentrations during local intrabrachial apelin infusions. At infusion rates >3 nmol/min, we detected a rise in plasma apelin concentrations accompanied by an increase in FBF in the noninfused arm, indicating spillover of infused apelin into the systemic circulation. This spillover limits interpretation of blood flow changes at the higher doses of apelin because of potential concomitant effects on myocardial contractility or activation of neurohumoral reflexes. However, at apelin doses ≤3 nmol/min, changes in blood flow can be solely ascribed to direct local vascular effects.

We have described the effects of exogenous apelin on resistance vessels in the forearm vascular bed. Although concordance between vasomotor responses in the forearm and other vascular beds is generally good (18), differences do exist and further studies will be needed to confirm our findings in other vascular beds such as the coronary circulation.

**Conclusions**

We have shown that acute apelin administration in vivo in man causes NO-mediated arterial vasodilation but does not appear to affect peripheral venous tone. Increasing evidence from pre-clinical models has suggested that apelin–APJ signaling mediates important effects on cardiovascular homeostasis. Our findings provide the strongest evidence to date of a role for the apelin-APJ system in human cardiovascular regulation.

**Acknowledgments**

The authors thank the staff in the Wellcome Trust Clinical Research Facility for their help with these studies.

---

**Reprint requests and correspondence:** Dr. Alan G. Japp, Centre for Cardiovascular Science, The University of Edinburgh, Chancellor’s Building, Edinburgh, EH16 4SB, United Kingdom. Email: alan.japp@ed.ac.uk.

**REFERENCES**


**Key Words:** apelin  •  APJ receptor  •  endothelium  •  vasodilator.